Clinically, NPRA serves as a prognostic biomarker in gastric/esophageal cancers, while NPRC agonists (e.g., C-ANP4-23) and NPRB-targeting dCNP show promising antitumor efficacy in preclinical models. The gene discussed is NPR2; the disease is esophageal cancer.